Skip to main content

Table 4 Observed change from baseline to week 24 by region in the placebo group

From: Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program

 

Eastern Europe/Turkey (n = 259a)

Western Europe/Israel (n = 254b)

USA/Canada (n = 145c)

South America/Mexico (n = 119d)

Asia (n = 53)

Australia/South Africa (n = 32e)

p value for equality of variances

ADAS-Cog, mean (SD)

0.32 (6.59)

1.40 (6.24)SA

0.55 (5.72)

−0.71 (5.32)WE

0.17 (5.28)

1.56 (5.89)

0.29

ADCS-CGIC, mean (SD)f

4.18 (0.95)WE

4.51 (1.03)EE,SA

4.39 (0.90)SA

3.98 (1.35)WE,US

4.30 (0.85)

4.41 (1.04)

< 0.0001

ADCS-ADL23, mean (SD)

−0.59 (7.59)WE

−3.21 (7.68)EE

−1.78 (8.45)

−1.44 (7.07)

−1.77 (5.71)

−2.76 (8.03)

0.60

NPI, mean (SD)

−1.03 (9.95)

0.45 (9.39)

−0.46 (10.53)

−1.39 (11.42)

−0.13 (6.44)

−1.73 (10.32)

0.66

MMSE, mean (SD)

0.10 (3.08)WE,US

−0.79 (2.80)EE

−0.77 (3.00)EE

−0.34 (2.34)

−0.58 (2.73)

−1.22 (3.03)

0.42

  1. ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive subscale, ADCS-ADL23 Alzheimer’s Disease Cooperative Study—Activities of Daily Living, 23-item version, ADCS-CGIC Alzheimer’s Disease Cooperative Study—Clinical Global Impression of Change, MMSE Mini–Mental State Examination, NPI Neuropsychiatric Inventory, SD standard deviation
  2. Pairwise comparisons: EEp < 0.05 versus Eastern Europe/Turkey; WEp < 0.05 versus Western Europe/Israel; USp < 0.05 versus USA/Canada; SAp < 0.05 versus South America/Mexico
  3. aExcept MMSE, n = 260
  4. bExcept ADCS-CGIC, n = 250
  5. cExcept ADCS-CGIC, n = 143
  6. dExcept ADCS-CGIC, n = 117
  7. eExcept ADCS-ADL23 and NPI, n = 33
  8. fMean (SD) score at week 24 is presented for ADCS-CGIC. The scale is itself a measure of change from baseline, meaning that change scores are not applicable. Scores > 4 indicate worsening